186 related articles for article (PubMed ID: 29129657)
1. Transport mechanism of lipid covered saquinavir pure drug nanoparticles in intestinal epithelium.
Xia D; He Y; Li Q; Hu C; Huang W; Zhang Y; Wan F; Wang C; Gan Y
J Control Release; 2018 Jan; 269():159-170. PubMed ID: 29129657
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation.
He Y; Xia DN; Li QX; Tao JS; Gan Y; Wang C
Acta Pharmacol Sin; 2015 Sep; 36(9):1151-60. PubMed ID: 26256404
[TBL] [Abstract][Full Text] [Related]
3. Self-Assembled Core-Shell-Type Lipid-Polymer Hybrid Nanoparticles: Intracellular Trafficking and Relevance for Oral Absorption.
Li Q; Xia D; Tao J; Shen A; He Y; Gan Y; Wang C
J Pharm Sci; 2017 Oct; 106(10):3120-3130. PubMed ID: 28559042
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier.
Beloqui A; Solinís MÁ; Gascón AR; del Pozo-Rodríguez A; des Rieux A; Préat V
J Control Release; 2013 Mar; 166(2):115-23. PubMed ID: 23266764
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles.
Kigen G; Edwards G
BMC Pharmacol Toxicol; 2018 Dec; 19(1):79. PubMed ID: 30509316
[TBL] [Abstract][Full Text] [Related]
6. Enhanced transport of nanocage stabilized pure nanodrug across intestinal epithelial barrier mimicking Listeria monocytogenes.
Xia D; Tao J; He Y; Zhu Q; Chen D; Yu M; Cui F; Gan Y
Biomaterials; 2015 Jan; 37():320-32. PubMed ID: 25453961
[TBL] [Abstract][Full Text] [Related]
7. Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux.
Jain R; Agarwal S; Mandava NK; Sheng Y; Mitra AK
Int J Pharm; 2008 Oct; 362(1-2):44-51. PubMed ID: 18620036
[TBL] [Abstract][Full Text] [Related]
8. Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.
Jain R; Duvvuri S; Kansara V; Mandava NK; Mitra AK
Int J Pharm; 2007 May; 336(2):233-40. PubMed ID: 17207946
[TBL] [Abstract][Full Text] [Related]
9. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats.
Usansky HH; Hu P; Sinko PJ
Drug Metab Dispos; 2008 May; 36(5):863-9. PubMed ID: 18256206
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir.
Wang Z; Pal D; Mitra AK
J Pharm Sci; 2012 Sep; 101(9):3199-213. PubMed ID: 22611042
[TBL] [Abstract][Full Text] [Related]
11. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.
Washington CB; Wiltshire HR; Man M; Moy T; Harris SR; Worth E; Weigl P; Liang Z; Hall D; Marriott L; Blaschke TF
Drug Metab Dispos; 2000 Sep; 28(9):1058-62. PubMed ID: 10950849
[TBL] [Abstract][Full Text] [Related]
12. Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats.
Li J; Liu Y; Zhang J; Yu X; Wang X; Zhao L
Drug Des Devel Ther; 2016; 10():3699-3706. PubMed ID: 27895462
[TBL] [Abstract][Full Text] [Related]
13. High-energy ball milling of saquinavir increases permeability across the buccal mucosa.
Rambharose S; Ojewole E; Branham M; Kalhapure R; Govender T
Drug Dev Ind Pharm; 2014 May; 40(5):639-48. PubMed ID: 24499179
[TBL] [Abstract][Full Text] [Related]
14. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
Jain R; Agarwal S; Majumdar S; Zhu X; Pal D; Mitra AK
Int J Pharm; 2005 Oct; 303(1-2):8-19. PubMed ID: 16137847
[TBL] [Abstract][Full Text] [Related]
15. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats.
Shibata N; Kageyama M; Kimura K; Tadano J; Hukushima H; Namiki H; Yoshikawa Y; Takada K
Biol Pharm Bull; 2004 Feb; 27(2):203-9. PubMed ID: 14758034
[TBL] [Abstract][Full Text] [Related]
17. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation.
Pathak SM; Musmade P; Dengle S; Karthik A; Bhat K; Udupa N
Eur J Pharm Sci; 2010 Nov; 41(3-4):440-51. PubMed ID: 20656025
[TBL] [Abstract][Full Text] [Related]
18. Enhanced systemic exposure of saquinavir via the concomitant use of curcumin-loaded solid dispersion in rats.
Kim SA; Kim SW; Choi HK; Han HK
Eur J Pharm Sci; 2013 Aug; 49(5):800-4. PubMed ID: 23748001
[TBL] [Abstract][Full Text] [Related]
19. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
20. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.
Vyas TK; Shahiwala A; Amiji MM
Int J Pharm; 2008 Jan; 347(1-2):93-101. PubMed ID: 17651927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
